Antonio Passaro: European Commission approves amivantamab

Antonio Passaro shared on LinkedIn:

“I’m proud to announce that, yesterday August 27, the European Commission has granted approval for amivantamab in combination with chemotherapy for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) progressing on or after osimertinib (MARIPOSA-2 combo)

One year after the presidential presentation at ESMO23, this approval is a significant leap forward in our mission to provide innovative and effective treatments for patients facing this challenging diagnosis. It’s inspiring to see how science and dedication can come together to offer new hope and improved outcomes for those in need.

Being part of this journey is incredibly rewarding, and I’m grateful to contribute to a future where advanced therapies continue to make a meaningful difference in patients’ lives.”

Source: Antonio Passaro/LinkedIn

Antonio Passaro MD PhD, a medical oncologist at the European Institute of Oncology in Milan, specializes in lung cancer research and treatment. he focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC).

Dr. Antonio Passaro is an Associate Editor for Lung Cancer Journal by Elsevier and the Chair of the ESMO Press & Media Affairs Committee. He is also a faculty member for the Lung and Other Thoracic Tumours faculty group and the ESMO-MCBS Extended Working Group. He also holds editorial positions and key roles in societies like ESMO and AIOM.